Compugen Ltd. (CGEN)

Biological Products, (No Diagnostic Substances) · market cap $225M · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-09 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Compugen Ltd. (CGEN) is an Israel-based clinical-stage predictive drug discovery company with a market cap of ~$196M and 74 employees. Its lead asset, COM701, is in Phase 2 development for ovarian cancer, with a key data readout estimated around March 2027. Financial details including cash, runway, and revenue are not disclosed in available facts.

The catalyst path

2026-11-09 (est.)Earningsimp 5/10
2027-03-15 (est.)Phase 2 · COM701imp 7/10
2027-03-31Data Readoutimp 5/10

Pipeline

Asset	Phase	Indication
COM701	Phase 2	Ovarian Cancer

Price & technical context

3-month

+2.6%

6-month

+6.4%

12-month

+59.2%

52-wk range

$1.47–$3.10

vs 50-day MA

-4.6%

vs 200-day MA

+4.0%

Realized vol

67.7%

Max drawdown

-54.1%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.